Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Combating food allergies with vaccine viruses

31.07.2013
Researchers of the Paul-Ehrlich-Institut have succeeded in preventing food allergy against chicken protein using a modified vaccine virus.

The viruses serve a dual function: They transfer genetic information of the allergen into the target cell of the immune system and they have an inherent immunomodulatory effect. The research results have been published in the online edition of the journal Allergy of 30 July 2013 (DOI 10.1111/all.12192)


Inflammation of intestinal mucosa in allergic mice (on the left; e.g. thickened basal layer) as compared to MVA-OVA-vaccinated mice with unimpaired intestinal mucosa (on the right side).
Paul-Ehrlich-Institut

Food allergies are on the increase in all industrialised countries, affecting around five per cent of all children and four per cent of all adults. Allergen avoidance is currently the only established treatment of choice. Specific immunotherapy using allergen extracts, which is common in the treatment of pollen allergies, has not yet been established for food allergies. Moreover, there is an inherent risk of serious adverse reactions including anaphylactic shock.

Researchers of the Paul-Ehrlich-Institut have therefore taken a completely novel approach towards immunotherapy of food allergy, which is based on modified vaccinia virus Ankara (MVA). MVA is a modified vaccine virus which has been found to be safe in several clinical trials in infection medicine. MVA facilitates transfer of the genetic information of the allergen to antigen presenting cells of the body. Cells infected with the virus begin to produce the allergen and present it to the immune system. Unlike the established immunotherapy of pollen or house dust mite allergy where allergen extracts are applied directly, the new method ascertains that the immune system does not come into contact with the allergen before allergen fragments are presented on the surface of antigen presenting cells. Serious allergic reactions as in the case of direct allergen uptake via food consumption can be ruled out.

Researchers in the Allergology and Virology Divisions at the Paul-Ehrlich-Institut had already been able to show that "vaccination" of mice with MVA carrying the gene for the chicken protein ovalbumin (MVA-OVA) prevented the usually considerable increase in allergy inducing IgE antibodies in response to exposure to the allergen [1].

Which clinical significance do these changes imply? To establish this, Dr Masako Toda, head of the Temporary Research Group "Experimental Allergy Models" at the PEI, and her co-workers developed a model of intestinal food allergy in mice. Sensitisation of mice to ovalbumin led to clinical symptoms such as diarrhoea, loss of bodyweight, and drop of body temperature. The researchers of the PEI were able to show that allergic symptoms could be prevented by vaccination with MVA-OVA and, what’s more, in collaboration with researchers of Tokyo University, Japan, they were able to establish that the vaccination could prevent inflammatory changes of the intestinal mucosa (see figure).

When examining the local immune response in the small intestine, the researchers were also able to prove – based on the modified release of the cytokines (inhibition of interleukin-4 and stimulation of interferon-gamma release) – that the adverse (allergic) response of TH2 helper cells was inhibited and the desired TH1 helper cell response was stimulated. ""This is the very result we wish to see in treating an allergy: the suppression of IgE and an increase in TH1 response"", Dr Stephan Scheurer explained the success of this approach. Dr Scheurer is the head of the Section "Recombinant Allergen Therapeutics" at the PEI.

The next steps to be taken by the researchers of the PEI will be to test how long this allergy protection will last and whether the therapy approach can be used to treat fully established allergies. ""If this is possible for our model allergen ovalbumin, we assume that the model can also be transferred to other food allergens"", explained Dr Scheurer.

Background

An allergy involves an excessive TH2 helper cell response. TH2 helper cells are a specialised group of lymphocytes of the immune system. During an allergic reaction, these cells respond to usually harmless antigens such as pollen, but also antigens in peanuts, hen's eggs, etc. Specific immunotherapy intends to re-establish the immune balance in favour of a TH1 helper response. In the above-described novel approach of immunotherapy, the modified virus Ankara not only serves as a transport vehicle of genetic information of the allergen but is also an effective immune modulator, since it creates a strong TH1 helper cell response against antigens. This process involves induction of allergen specific IgG2a antibodies, which can act as blocking antibodies, as well as cytokines (interferon-gamma) which counteract allergic reactions. This helps to restore a normal immune response.

Literature

[1] Albrecht M, Suezer Y, Staib C, Sutter G, Vieths S, Reese G (2008): Vaccination with a Modified Vaccinia Virus Ankara-based vaccine protects mice from allergic sensitization. J Gene Med 10: 1324-1333. Online-Abstract.

Original publication

Bohnen C, Wangorsch A, Schülke S, Nakajima-Adachi H, Hachimura S, Burggraf M, Süzer Y, Schwantes A, Sutter G, Waibler Z, Reese G, Toda M, Scheurer S, Vieths S (2013): Vaccination with recombinant modified vaccinia virus1 Ankara prevents the onset of intestinal allergy in mice.

Allergy Jul 30 [Epub ahead of print].

Weitere Informationen:

http://onlinelibrary.wiley.com/doi/10.1111/all.12192/abstract
- Publications Abstract
http://www.ncbi.nlm.nih.gov/pubmed/18816482?ordinalpos=60&itool=EntrezSystem2.
PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
Abstract of J Gene Med-Paper
http://www.pei.de/EN/information/journalists-press/press-releases/2013/03-combating-food-allergies-with-vaccine-viruses.html

Press release on PEI-Website

Dr. Susanne Stöcker | idw
Further information:
http://www.pei.de/

More articles from Life Sciences:

nachricht A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau

nachricht On the way to developing a new active ingredient against chronic infections
18.08.2017 | Deutsches Zentrum für Infektionsforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>